Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

BMO maintains Novo Nordisk stock Outperform rating, $105 target ...

The company agreed to pay up to $2 billion for the rights to UBT251, a developmental weight-loss and obesity drug from Chinese pharmaceutical company United Bio-Technology (Hengqin), as it looks ...

A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the federal government could have significant impact on this. Pharmaceutical ...

Dubai Advances Autonomous Taxi Deployment with Strategic Partnerships // Market cycles: leveraging seasonal trends with Octa Broker // Eric Trump Ventures into Bitcoin Mining Foll ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic ...

This decision gains significance as Novo Nordisk enters a licensing agreement for a similar drug, UBT251, potentially validating Eli Lilly’s approach. Jefferies also affirmed a Buy rating with a ...

Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4).

But with UBT251 still in early-stage trials, Lilly's blockbuster could hit the market first, leaving Novo Nordisk playing catch-up. Novo Nordisk's weight loss empire is facing pressure on multiple ...